1
|
Paramshetti S, Angolkar M, Talath S, Osmani RAM, Spandana A, Al Fatease A, Hani U, Ramesh KVRNS, Singh E. Unravelling the in vivo dynamics of liposomes: Insights into biodistribution and cellular membrane interactions. Life Sci 2024; 346:122616. [PMID: 38599316 DOI: 10.1016/j.lfs.2024.122616] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2023] [Revised: 03/21/2024] [Accepted: 04/05/2024] [Indexed: 04/12/2024]
Abstract
Liposomes, as a colloidal drug delivery system dating back to the 1960s, remain a focal point of extensive research and stand as a highly efficient drug delivery method. The amalgamation of technological and biological advancements has propelled their evolution, elevating them to their current status. The key attributes of biodegradability and biocompatibility have been instrumental in driving substantial progress in liposome development. Demonstrating a remarkable ability to surmount barriers in drug absorption, enhance stability, and achieve targeted distribution within the body, liposomes have become pivotal in pharmaceutical research. In this comprehensive review, we delve into the intricate details of liposomal drug delivery systems, focusing specifically on their pharmacokinetics and cell membrane interactions via fusion, lipid exchange, endocytosis etc. Emphasizing the nuanced impact of various liposomal characteristics, we explore factors such as lipid composition, particle size, surface modifications, charge, dosage, and administration routes. By dissecting the multifaceted interactions between liposomes and biological barriers, including the reticuloendothelial system (RES), opsonization, enhanced permeability and retention (EPR) effect, ATP-binding cassette (ABC) phenomenon, and Complement Activation-Related Pseudoallergy (CARPA) effect, we provide a deeper understanding of liposomal behaviour in vivo. Furthermore, this review addresses the intricate challenges associated with translating liposomal technology into practical applications, offering insights into overcoming these hurdles. Additionally, we provide a comprehensive analysis of the clinical adoption and patent landscape of liposomes across diverse biomedical domains, shedding light on their potential implications for future research and therapeutic developments.
Collapse
Affiliation(s)
- Sharanya Paramshetti
- Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education and Research (JSS AHER), Mysuru 570015, Karnataka, India.
| | - Mohit Angolkar
- Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education and Research (JSS AHER), Mysuru 570015, Karnataka, India.
| | - Sirajunisa Talath
- Department of Pharmaceutical Chemistry, RAK College of Pharmacy, RAK Medical and Health Sciences University, Ras Al Khaimah 11172, United Arab Emirates.
| | - Riyaz Ali M Osmani
- Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education and Research (JSS AHER), Mysuru 570015, Karnataka, India.
| | - Asha Spandana
- Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education and Research (JSS AHER), Mysuru 570015, Karnataka, India.
| | - Adel Al Fatease
- Department of Pharmaceutics, College of Pharmacy, King Khalid University, Abha 61421, Saudi Arabia.
| | - Umme Hani
- Department of Pharmaceutics, College of Pharmacy, King Khalid University, Abha 61421, Saudi Arabia.
| | - K V R N S Ramesh
- Department of Pharmaceutics, RAK College of Pharmacy, RAK Medical and Health Sciences University, Ras Al Khaimah 11172, United Arab Emirates.
| | - Ekta Singh
- Department of Biochemistry & Molecular Biology, University of Texas Medical Branch, Galveston, TX, United States.
| |
Collapse
|
2
|
Larsen NW, Kostrikov S, Hansen MB, Hjørringgaard CU, Larsen NB, Andresen TL, Kristensen K. Interactions of oral permeation enhancers with lipid membranes in simulated intestinal environments. Int J Pharm 2024; 654:123957. [PMID: 38430950 DOI: 10.1016/j.ijpharm.2024.123957] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2023] [Revised: 02/17/2024] [Accepted: 02/28/2024] [Indexed: 03/05/2024]
Abstract
The oral bioavailability of therapeutic peptides is generally low. To increase peptide transport across the gastrointestinal barrier, permeation enhancers are often used. Despite their widespread use, mechanistic knowledge of permeation enhancers is limited. To address this, we here investigate the interactions of six commonly used permeation enhancers with lipid membranes in simulated intestinal environments. Specifically, we study the interactions of the permeation enhancers sodium caprate, dodecyl maltoside, sodium cholate, sodium dodecyl sulfate, melittin, and penetratin with epithelial cell-like model membranes. To mimic the molecular composition of the real intestinal environment, the experiments are performed with two peptide drugs, salmon calcitonin and desB30 insulin, in fasted-state simulated intestinal fluid. Besides providing a comparison of the membrane interactions of the studied permeation enhancers, our results demonstrate that peptide drugs as well as intestinal-fluid components may substantially change the membrane activity of permeation enhancers. This highlights the importance of testing permeation enhancement in realistic physiological environments and carefully choosing a permeation enhancer for each individual peptide drug.
Collapse
Affiliation(s)
- Nanna Wichmann Larsen
- DTU Health Tech, Department of Health Technology, Technical University of Denmark, 2800 Kgs. Lyngby, Denmark; Center for Intestinal Absorption and Transport of Biopharmaceuticals, Technical University of Denmark, 2800 Kgs. Lyngby, Denmark
| | - Serhii Kostrikov
- DTU Health Tech, Department of Health Technology, Technical University of Denmark, 2800 Kgs. Lyngby, Denmark; Center for Intestinal Absorption and Transport of Biopharmaceuticals, Technical University of Denmark, 2800 Kgs. Lyngby, Denmark
| | - Morten Borre Hansen
- DTU Health Tech, Department of Health Technology, Technical University of Denmark, 2800 Kgs. Lyngby, Denmark; Center for Intestinal Absorption and Transport of Biopharmaceuticals, Technical University of Denmark, 2800 Kgs. Lyngby, Denmark
| | - Claudia Ulrich Hjørringgaard
- DTU Health Tech, Department of Health Technology, Technical University of Denmark, 2800 Kgs. Lyngby, Denmark; Center for Intestinal Absorption and Transport of Biopharmaceuticals, Technical University of Denmark, 2800 Kgs. Lyngby, Denmark
| | - Niels Bent Larsen
- DTU Health Tech, Department of Health Technology, Technical University of Denmark, 2800 Kgs. Lyngby, Denmark; Center for Intestinal Absorption and Transport of Biopharmaceuticals, Technical University of Denmark, 2800 Kgs. Lyngby, Denmark
| | - Thomas Lars Andresen
- DTU Health Tech, Department of Health Technology, Technical University of Denmark, 2800 Kgs. Lyngby, Denmark; Center for Intestinal Absorption and Transport of Biopharmaceuticals, Technical University of Denmark, 2800 Kgs. Lyngby, Denmark.
| | - Kasper Kristensen
- DTU Health Tech, Department of Health Technology, Technical University of Denmark, 2800 Kgs. Lyngby, Denmark; Center for Intestinal Absorption and Transport of Biopharmaceuticals, Technical University of Denmark, 2800 Kgs. Lyngby, Denmark.
| |
Collapse
|
3
|
Viera Herrera C, O'Connor PM, Ratrey P, Paul Ross R, Hill C, Hudson SP. Anionic liposome formulation for oral delivery of thuricin CD, a potential antimicrobial peptide therapeutic. Int J Pharm 2024; 654:123918. [PMID: 38401875 PMCID: PMC7615751 DOI: 10.1016/j.ijpharm.2024.123918] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2023] [Revised: 01/30/2024] [Accepted: 02/16/2024] [Indexed: 02/26/2024]
Abstract
Thuricin CD is a two-peptide antimicrobial produced by Bacillus thuringiensis. Unlike previous antibiotics, it has shown narrow spectrum activity against Clostridioides difficile, a bacterium capable of causing infectious disease in the colon. However, peptide antibiotics have stability, solubility, and permeability problems that can affect their performance in vivo. This work focuses on the bioactivity and bioavailability of thuricin CD with a view to developing a formulation for delivery of active thuricin CD peptides through the gastrointestinal tract (GIT) for local delivery in the colon. The results indicate that thuricin CD is active at low concentrations only when both peptides are present. While thuricin CD was degraded by proteases and was unstable and poorly soluble in gastric fluid, it showed increased solubility in intestinal fluid, probably due to micelle encapsulation. Based on this, thuricin CD was encapsulated in anionic liposomes, which showed increased activity compared to the free peptide, maintained activity after exposure to pepsin in gastric fluid and intestinal fluid, was stable in suspension for over 21 days at room temperature and for 60 days at 4 °C, and exhibited no toxicity to epithelial intestinal cells. These findings suggest that an anionic lipid-based nano formulation may be a promising approach for local oral delivery of thuricin CD.
Collapse
Affiliation(s)
- Camila Viera Herrera
- Department of Chemical Sciences, Bernal Institute, University of Limerick, Ireland
| | - Paula M O'Connor
- Food Biosciences, Teagasc, Moorepark Food Research Centre, Fermoy, Co. Cork, Ireland; APC Microbiome Ireland Cork, Cork, Ireland
| | - Poonam Ratrey
- Department of Chemical Sciences, Bernal Institute, University of Limerick, Ireland
| | - R Paul Ross
- APC Microbiome Ireland Cork, Cork, Ireland; School of Microbiology, University College Cork, College Road, Cork, Ireland
| | - Colin Hill
- APC Microbiome Ireland Cork, Cork, Ireland; School of Microbiology, University College Cork, College Road, Cork, Ireland
| | - Sarah P Hudson
- Department of Chemical Sciences, Bernal Institute, University of Limerick, Ireland.
| |
Collapse
|
4
|
Zhang Y, Belaid M, Luo X, Daci A, Limani R, Mantaj J, Zilbauer M, Nayak K, Vllasaliu D. Probing milk extracellular vesicles for intestinal delivery of RNA therapies. J Nanobiotechnology 2023; 21:406. [PMID: 37924132 PMCID: PMC10623793 DOI: 10.1186/s12951-023-02173-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2023] [Accepted: 10/21/2023] [Indexed: 11/06/2023] Open
Abstract
BACKGROUND Oral delivery remains unattainable for nucleic acid therapies. Many nanoparticle-based drug delivery systems have been investigated for this, but most suffer from poor gut stability, poor mucus diffusion and/or inefficient epithelial uptake. Extracellular vesicles from bovine milk (mEVs) possess desirable characteristics for oral delivery of nucleic acid therapies since they both survive digestion and traverse the intestinal mucosa. RESULTS Using novel tools, we comprehensively examine the intestinal delivery of mEVs, probing whether they could be used as, or inform the design of, nanoparticles for oral nucleic acid therapies. We show that mEVs efficiently translocate across the Caco-2 intestinal model, which is not compromised by treatment with simulated intestinal fluids. For the first time, we also demonstrate transport of mEVs in novel 3D 'apical-out' and monolayer-based human intestinal epithelial organoids (IEOs). Importantly, mEVs loaded with small interfering RNA (siRNA) induced (glyceraldehyde 3-phosphate dehydrogenase, GAPDH) gene silencing in macrophages. Using inflammatory bowel disease (IBD) as an example application, we show that administration of anti-tumour necrosis factor alpha (TNFα) siRNA-loaded mEVs reduced inflammation in a IBD rat model. CONCLUSIONS Together, this work demonstrates that mEVs could either act as natural and safe systems for oral delivery or nucleic acid therapies, or inform the design of synthetic systems for such application.
Collapse
Affiliation(s)
- Yunyue Zhang
- Institute of Pharmaceutical Science, School of Cancer and Pharmaceutical Science, King's College London, London, SE1 9NH, UK
| | - Mona Belaid
- Institute of Pharmaceutical Science, School of Cancer and Pharmaceutical Science, King's College London, London, SE1 9NH, UK
| | - Xiang Luo
- Institute of Pharmaceutical Science, School of Cancer and Pharmaceutical Science, King's College London, London, SE1 9NH, UK
| | - Armond Daci
- Faculty of Medicine, University of Prishtina "Hasan Prishtina", 10000, Prishtina, Kosovo
| | - Rinë Limani
- Faculty of Medicine, University of Prishtina "Hasan Prishtina", 10000, Prishtina, Kosovo
| | - Julia Mantaj
- Institute of Pharmaceutical Science, School of Cancer and Pharmaceutical Science, King's College London, London, SE1 9NH, UK
- School of Life Sciences, Faculty of Science and Engineering, Anglia Ruskin University, Cambridge, CB1 1PT, UK
| | - Matthias Zilbauer
- Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, CB2 0AW, UK
- Department of Paediatrics, University of Cambridge, Cambridge, CB2 0QQ, UK
| | - Komal Nayak
- Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, CB2 0AW, UK
- Department of Paediatrics, University of Cambridge, Cambridge, CB2 0QQ, UK
| | - Driton Vllasaliu
- Institute of Pharmaceutical Science, School of Cancer and Pharmaceutical Science, King's College London, London, SE1 9NH, UK.
| |
Collapse
|
5
|
Fadaei MR, Mohammadi M, Fadaei MS, Jaafari MR. The crossroad of nanovesicles and oral delivery of insulin. Expert Opin Drug Deliv 2023; 20:1387-1413. [PMID: 37791986 DOI: 10.1080/17425247.2023.2266992] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2023] [Accepted: 10/02/2023] [Indexed: 10/05/2023]
Abstract
INTRODUCTION Diabetes mellitus is one of the challenging health problems worldwide. Multiple daily subcutaneous injection of insulin causes poor compliance in patients. Development of efficient oral formulations to improve the quality of life of such patients has been an important goal in pharmaceutical industry. However, due to serious issues such as low bioavailability and instability, it has not been achieved yet. AREAS COVERED Due to functional properties of the vesicles and the fact that hepatic-directed vesicles of insulin could reach the clinical phases, we focused on three main vesicular delivery systems for oral delivery of insulin: liposomes, niosomes, and polymersomes. Recent papers were thoroughly discussed to provide a broad overview of such oral delivery systems. EXPERT OPINION Although conventional liposomes are unstable in the presence of bile salts, their further modifications such as surface coating could increase their stability in the GI tract. Bilosomes showed good flexibility and stability in GI fluids. Also, niosomes were stable, but they could not induce significant hypoglycemia in animal studies. Although polymersomes were effective, they are expensive and there are some issues about their safety and industrial scale-up. Also, we believe that other modifications such as addition of a targeting agent or surface coating of the vesicles could significantly increase the bioavailability of insulin-loaded vesicles.
Collapse
Affiliation(s)
- Mohammad Reza Fadaei
- Department of Pharmaceutics, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Marzieh Mohammadi
- Department of Pharmaceutics, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
- Targeted Drug Delivery Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Mohammad Saleh Fadaei
- Student Research Committee, School of Pharmacy, Mashhad University of Medical Science, Mashhad, Iran
| | - Mahmoud Reza Jaafari
- Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
- Department of Pharmaceutical Nanotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
| |
Collapse
|
6
|
Ye S, Cheng Y, Guo Z, Wang X, Wei W. A lipid toolbox of sugar alcohol fatty acid monoesters for single-component lipid nanoparticles with temperature-controlled release. Colloids Surf B Biointerfaces 2023; 228:113426. [PMID: 37399694 DOI: 10.1016/j.colsurfb.2023.113426] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2023] [Revised: 06/10/2023] [Accepted: 06/21/2023] [Indexed: 07/05/2023]
Abstract
This study aimed to prepare single-component LNPs with sugar alcohol fatty acid monoesters for temperature-controlled release. In total, 20 kinds of lipids with a series of sugar alcohol head groups (ethylene glycol, glycerol, erythritol, xylitol and sorbitol) and fatty acyl tails (12:0, 14:0, 16:0 and 18:0) were synthesised via lipase-catalysed esterification. Their physicochemical properties and upper/lower critical solution temperature (LCST/USCT) were analysed. Two groups of mixed lipids, 78 % ethylene glycol lauric acid monoester + 22 % sorbitol stearic acid monoester (LNP-1) and 90 % ethylene glycol lauric acid monoester + 10 % xylitol myristic acid monoester (LNP-2), had LCST/USCT of approximately 37 °C, which formed empty LNPs using the emulsification-diffusion method. These two mixed lipids were prepared for LNPs loaded with curcumin, showing high encapsulation (>90 %), mean particle sizes of approximately 250 nm and low polydispersity index (≤0.2). These lipids have the potential for tailor-made LNPs achieving thermo-responsivity in delivering bioactive agents and drugs.
Collapse
Affiliation(s)
- Shengyuan Ye
- State Key Laboratory of Food Science and Resources, Jiangnan University, Wuxi 214122, China; Collaborative Innovation Center of Food Safety and Quality Control in Jiangsu Province, School of Food Science and Technology, Jiangnan University, Wuxi 214122, China
| | - Yang Cheng
- State Key Laboratory of Food Science and Resources, Jiangnan University, Wuxi 214122, China; Collaborative Innovation Center of Food Safety and Quality Control in Jiangsu Province, School of Food Science and Technology, Jiangnan University, Wuxi 214122, China
| | - Zheng Guo
- Department of Biological and Chemical Engineering, Faculty of Technical Science, Aarhus University, 8000 Aarhus, Denmark
| | - Xingguo Wang
- State Key Laboratory of Food Science and Resources, Jiangnan University, Wuxi 214122, China; Collaborative Innovation Center of Food Safety and Quality Control in Jiangsu Province, School of Food Science and Technology, Jiangnan University, Wuxi 214122, China
| | - Wei Wei
- State Key Laboratory of Food Science and Resources, Jiangnan University, Wuxi 214122, China; Collaborative Innovation Center of Food Safety and Quality Control in Jiangsu Province, School of Food Science and Technology, Jiangnan University, Wuxi 214122, China.
| |
Collapse
|
7
|
Guo C, Zhu X, Yuan H, Liu H, Zhang Y, Yin T, He H, Gou J, Tang X. Chitosan-Coated Liposomes: The Strategy to Reduce Intestinal Toxicity and Improve Bioavailability of Oral Vinorelbine. AAPS PharmSciTech 2022; 23:163. [PMID: 35680728 DOI: 10.1208/s12249-022-02308-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2022] [Accepted: 05/15/2022] [Indexed: 11/30/2022] Open
Abstract
In recent years, the oral administration of vinorelbine has gradually replaced intravenous administration in the treatment of several types of tumors. Even though the risk of phlebitis is avoided with oral administration, oral vinorelbine is still not a highly patient-compliant route due to the severe gastrointestinal toxicity. Vinorelbine-loaded liposomes with high encapsulation efficiency and suitable particle size were prepared using the ammonium sulfate gradient method. Chitosan-coated liposomes showed the slowest in vitro release compared to uncoated liposomes and vinorelbine solution. No damage was observed in the intestinal epithelial cells of mice orally administered with coated vinorelbine liposomes due to the low presence of the free drug in the gastrointestinal tract and the LD50 was increased from 129.83 to 182.25 mg/kg compared to oral vinorelbine solution. In addition, the positive surface potential of chitosan-coating endowed liposomes with mucosal adhesive function, delaying the time to reach the peak plasma concentration of vinorelbine from 1 to 4 h after administration. And bioavailability was increased to 2.1-fold compared to vinorelbine solution. In short, a new strategy to address the severe gastrointestinal side effects of oral vinorelbine has been developed.
Collapse
Affiliation(s)
- Chen Guo
- Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, 110016, Liaoning, People's Republic of China
| | - Xichun Zhu
- Center for Drug and Cosmetic Safety Evaluation and Research, Gansu Provincial Institute of Drug Control, 7 Yinan Road, Anning District, Lanzhou, 730070, Gansu, People's Republic of China
| | - Haoyang Yuan
- Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, 110016, Liaoning, People's Republic of China
| | - Haoyu Liu
- Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, 110016, Liaoning, People's Republic of China
| | - Yu Zhang
- Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, 110016, Liaoning, People's Republic of China
| | - Tian Yin
- School of Functional Food and Wine, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, 110016, Liaoning, People's Republic of China
| | - Haibing He
- Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, 110016, Liaoning, People's Republic of China
| | - Jingxin Gou
- Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, 110016, Liaoning, People's Republic of China.
| | - Xing Tang
- Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, 110016, Liaoning, People's Republic of China.
| |
Collapse
|
8
|
Liposomal Formulation for Oral Delivery of Cyclosporine A: Usefulness as a Semisolid-Dispersion System. Pharm Res 2022; 39:977-987. [PMID: 35501532 DOI: 10.1007/s11095-022-03276-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2022] [Accepted: 04/24/2022] [Indexed: 10/18/2022]
Abstract
PURPOSE This study aims to understand the process and mechanism of oral drug absorption from liposomes and to verify the usefulness of liposomal formulation for poorly soluble drugs. METHODS Cyclosporine A (CsA) was used as a model drug and entrapped into Dipalmitoylphosphatidylcholine (DPPC) and distearoylphosphatidylcholine (DSPC) liposomes. Molecular state of CsA in the liposomes was analyzed using powder X-ray diffraction (PXRD) and polarized light microscopy (PLM). Release profiles of CsA from liposomes were observed in fasted state simulated intestinal fluid (FaSSIF). Oral absorption of CsA from liposomal formulations were investigated in rats. RESULTS PXRD and PLM analyses suggested that CsA exists in the lipid layer of liposomes as a molecular dispersed state. Although both liposomes retained CsA stably in the simple buffer, DPPC liposomes quickly released CsA within 10 min in FaSSIF due to the interaction with bile acid. In contrast, effect of bile acid was negligible in DSPC, indicating a high resistivity to membrane perturbation. Oral bioavailability of CsA from liposomal formulations were almost comparable with that from a marketed product (Neoral). However, the absorption profiles were clearly different. CsA was absorbed quickly from DPPC liposomes and Neoral, while sustained absorption profile was observed from DSPC liposomes. Further study in which ritonavir was co-entrapped in the liposomes with CsA showed the higher efficacy of ritonavir to increase oral bioavailability of CsA. CONCLUSION Liposomes allows the appropriate formulation design for oral delivery of poorly soluble drugs, not only to increase the extent but also to control the rate of absorption.
Collapse
|
9
|
Selmani A, Seibert E, Tetyczka C, Kuehnelt D, Vidakovic I, Kornmueller K, Absenger-Novak M, Radatović B, Vinković Vrček I, Leitinger G, Fröhlich E, Bernkop-Schnürch A, Roblegg E, Prassl R. Thiolated Chitosan Conjugated Liposomes for Oral Delivery of Selenium Nanoparticles. Pharmaceutics 2022; 14:pharmaceutics14040803. [PMID: 35456640 PMCID: PMC9032237 DOI: 10.3390/pharmaceutics14040803] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2022] [Revised: 04/01/2022] [Accepted: 04/05/2022] [Indexed: 02/01/2023] Open
Abstract
This study aimed to design a hybrid oral liposomal delivery system for selenium nanoparticles (Lip-SeNPs) to improve the bioavailability of selenium. Thiolated chitosan, a multifunctional polymer with mucoadhesive properties, was used for surface functionalization of Lip-SeNPs. Selenium nanoparticle (SeNP)-loaded liposomes were manufactured by a single step microfluidics-assisted chemical reduction and assembling process. Subsequently, chitosan-N-acetylcysteine was covalently conjugated to the preformed Lip-SeNPs. The Lip-SeNPs were characterized in terms of composition, morphology, size, zeta potential, lipid organization, loading efficiency and radical scavenging activity. A co-culture system (Caco-2:HT29-MTX) that integrates mucus secreting and enterocyte-like cell types was used as a model of the human intestinal epithelium to determine adsorption, mucus penetration, release and transport properties of Lip-SeNPs in vitro. Thiolated Lip-SeNPs were positively charged with an average size of about 250 nm. Thiolated Lip-SeNPs tightly adhered to the mucus layer without penetrating the enterocytes. This finding was consistent with ex vivo adsorption studies using freshly excised porcine small intestinal tissues. Due to the improved mucoadhesion and retention in a simulated microenvironment of the small intestine, thiolated Lip-SeNPs might be a promising tool for oral selenium delivery.
Collapse
Affiliation(s)
- Atiđa Selmani
- Department of Pharmaceutical Technology and Biopharmacy, Institute of Pharmaceutical Sciences, University of Graz, 8010 Graz, Austria; (A.S.); (C.T.); (E.R.)
| | - Elisabeth Seibert
- Division of Biophysics, Gottfried Schatz Research Center for Cell Signaling, Metabolism and Aging, Medical University of Graz, 8010 Graz, Austria; (E.S.); (I.V.); (K.K.)
| | - Carolin Tetyczka
- Department of Pharmaceutical Technology and Biopharmacy, Institute of Pharmaceutical Sciences, University of Graz, 8010 Graz, Austria; (A.S.); (C.T.); (E.R.)
| | - Doris Kuehnelt
- Institute of Chemistry, Analytical Chemistry, NAWI Graz, University of Graz, 8010 Graz, Austria;
| | - Ivan Vidakovic
- Division of Biophysics, Gottfried Schatz Research Center for Cell Signaling, Metabolism and Aging, Medical University of Graz, 8010 Graz, Austria; (E.S.); (I.V.); (K.K.)
| | - Karin Kornmueller
- Division of Biophysics, Gottfried Schatz Research Center for Cell Signaling, Metabolism and Aging, Medical University of Graz, 8010 Graz, Austria; (E.S.); (I.V.); (K.K.)
| | - Markus Absenger-Novak
- Center for Medical Research, Medical University of Graz, 8010 Graz, Austria; (M.A.-N.); (E.F.)
| | - Borna Radatović
- Center of Excellence for Advanced Materials and Sensing Devices, Institute of Physics, 10000 Zagreb, Croatia;
| | | | - Gerd Leitinger
- Division of Cell Biology, Histology and Embryology, Gottfried Schatz Research Center for Cell Signaling, Metabolism and Aging, Medical University of Graz, 8010 Graz, Austria;
| | - Eleonore Fröhlich
- Center for Medical Research, Medical University of Graz, 8010 Graz, Austria; (M.A.-N.); (E.F.)
| | - Andreas Bernkop-Schnürch
- Department of Pharmaceutical Technology, Center for Chemistry and Biomedicine, Institute of Pharmacy, University of Innsbruck, 6020 Innsbruck, Austria;
| | - Eva Roblegg
- Department of Pharmaceutical Technology and Biopharmacy, Institute of Pharmaceutical Sciences, University of Graz, 8010 Graz, Austria; (A.S.); (C.T.); (E.R.)
| | - Ruth Prassl
- Division of Biophysics, Gottfried Schatz Research Center for Cell Signaling, Metabolism and Aging, Medical University of Graz, 8010 Graz, Austria; (E.S.); (I.V.); (K.K.)
- Correspondence: ; Tel.: +43-316-385-71695
| |
Collapse
|
10
|
Sheikholeslami B, Lam NW, Dua K, Haghi M. Exploring the impact of physicochemical properties of liposomal formulations on their in vivo fate. Life Sci 2022; 300:120574. [DOI: 10.1016/j.lfs.2022.120574] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2022] [Revised: 04/12/2022] [Accepted: 04/18/2022] [Indexed: 12/16/2022]
|
11
|
Deshayes C, Arafath MN, Apaire-Marchais V, Roger E. Drug Delivery Systems for the Oral Administration of Antimicrobial Peptides: Promising Tools to Treat Infectious Diseases. FRONTIERS IN MEDICAL TECHNOLOGY 2022; 3:778645. [PMID: 35146486 PMCID: PMC8821882 DOI: 10.3389/fmedt.2021.778645] [Citation(s) in RCA: 19] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2021] [Accepted: 12/06/2021] [Indexed: 12/12/2022] Open
Abstract
Antimicrobial peptides (AMPs) have a great potential to face the global expansion of antimicrobial resistance (AMR) associated to the development of multidrug-resistant (MDR) pathogens. AMPs are usually composed of 10–50 amino acids with a broad structural diversity and present a range of antimicrobial activities. Unfortunately, even if the oral route is the most convenient one, currently approved therapeutic AMPs are mostly administrated by the intravenous route. Thus, the development of novel drug delivery systems (DDSs) represents a promising opportunity to protect AMPs from chemical and enzymatic degradation through the gastrointestinal tract and to increase intestinal permeability leading to high bioavailability. In this review, the classification and properties as well as mechanisms of the AMPs used in infectiology are first described. Then, the different pharmaceutical forms existing in the market for oral administration are presented. Finally, the formulation technologies, including microparticle- and nanoparticle-based DDSs, used to improve the oral bioavailability of AMPs are reviewed.
Collapse
Affiliation(s)
| | | | | | - Emilie Roger
- University of Angers, INSERM, CNRS, MINT, SFR ICAT, Angers, France
- *Correspondence: Emilie Roger
| |
Collapse
|
12
|
Can A, Tyler AI, Mackie AR. Potential use of bile salts in lipid self-assembled systems for the delivery of phytochemicals. Curr Opin Colloid Interface Sci 2021. [DOI: 10.1016/j.cocis.2021.101502] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
13
|
Emulsification and gelation as a tool for iron encapsulation in food-grade systems. Lebensm Wiss Technol 2021. [DOI: 10.1016/j.lwt.2021.111895] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
14
|
Mühlberg E, Burtscher M, Umstätter F, Fricker G, Mier W, Uhl P. Trends in liposomal nanocarrier strategies for the oral delivery of biologics. Nanomedicine (Lond) 2021; 16:1813-1832. [PMID: 34269068 DOI: 10.2217/nnm-2021-0177] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
The number of approved macromolecular drugs such as peptides, proteins and antibodies steadily increases. Since drugs with high molecular weight are commonly not suitable for oral delivery, research on carrier strategies enabling oral administration is of vital interest. In past decades, nanocarriers, in particular liposomes, have been exhaustively investigated as oral drug-delivery platform. Despite their successful application as parenteral delivery vehicles, liposomes have up to date not succeeded for oral administration. However, a plenitude of approaches aiming to increase the oral bioavailability of macromolecular drugs administered by liposomal formulations has been published. Here, we summarize the strategies published in the last 10 years (vaccine strategies excluded) with a main focus on strategies proven efficient in animal models.
Collapse
Affiliation(s)
- Eric Mühlberg
- Department of Nuclear Medicine, Heidelberg University Hospital, Im Neuenheimer Feld 400, Heidelberg, 69120, Germany
| | - Mira Burtscher
- Department of Nuclear Medicine, Heidelberg University Hospital, Im Neuenheimer Feld 400, Heidelberg, 69120, Germany
| | - Florian Umstätter
- Department of Nuclear Medicine, Heidelberg University Hospital, Im Neuenheimer Feld 400, Heidelberg, 69120, Germany
| | - Gert Fricker
- Department of Pharmaceutical Technology & Biopharmacy, Institute for Pharmacy & Molecular Biotechnology, Ruprecht-Karls University, Im Neuenheimer Feld 329, Heidelberg, 69120, Germany
| | - Walter Mier
- Department of Nuclear Medicine, Heidelberg University Hospital, Im Neuenheimer Feld 400, Heidelberg, 69120, Germany
| | - Philipp Uhl
- Department of Nuclear Medicine, Heidelberg University Hospital, Im Neuenheimer Feld 400, Heidelberg, 69120, Germany
| |
Collapse
|
15
|
Grossen P, Portmann M, Koller E, Duschmalé M, Minz T, Sewing S, Pandya NJ, van Geijtenbeek SK, Ducret A, Kusznir EA, Huber S, Berrera M, Lauer ME, Ringler P, Nordbo B, Jensen ML, Sladojevich F, Jagasia R, Alex R, Gamboni R, Keller M. Evaluation of bovine milk extracellular vesicles for the delivery of locked nucleic acid antisense oligonucleotides. Eur J Pharm Biopharm 2020; 158:198-210. [PMID: 33248268 DOI: 10.1016/j.ejpb.2020.11.012] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2020] [Revised: 11/18/2020] [Accepted: 11/21/2020] [Indexed: 12/14/2022]
Abstract
The natural capacity of extracellular vesicles (EVs) to transport their payload to recipient cells has raised big interest to repurpose EVs as delivery vehicles for xenobiotics. In the present study, bovine milk-derived EVs (BMEVs) were investigated for their potential to shuttle locked nucleic acid-modified antisense oligonucleotides (LNA ASOs) into the systemic circulation after oral administration. To this end, a broad array of analytical methods including proteomics and lipidomics were used to thoroughly characterize BMEVs. We found that additional purification by density gradients efficiently reduced levels of non-EV associated proteins. The potential of BMEVs to functionally transfer LNA ASOs was tested using advanced in vitro systems (i.e. hPSC-derived neurons and primary human cells). A slight increase in cellular LNA ASO internalization and target gene reduction was observed when LNA ASOs were delivered using BMEVs. When dosed orally in mice, only a small fraction (about 1% of total administered dose) of LNA ASOs was recovered in the peripheral tissues liver and kidney, however, no significant reduction in target gene expression (i.e. functional knockdown) was observed.
Collapse
Affiliation(s)
- Philip Grossen
- Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - Michaela Portmann
- Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - Erich Koller
- Roche Pharma Research and Early Development, DMPK, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - Martina Duschmalé
- Roche Pharma Research and Early Development, iSafe, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - Tanja Minz
- Roche Pharma Research and Early Development, iSafe, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - Sabine Sewing
- Roche Pharma Research and Early Development, iSafe, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - Nikhil Janak Pandya
- Roche Pharma Research and Early Development, Biomics and Pathology, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland; Roche Pharma Research and Early Development, Neurology and Rare Diseases Disease Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - Sabine Kux van Geijtenbeek
- Roche Pharma Research and Early Development, Biomics and Pathology, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - Axel Ducret
- Roche Pharma Research and Early Development, Biomics and Pathology, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - Eric-André Kusznir
- Roche Pharma Research and Early Development, Biomics and Pathology, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - Sylwia Huber
- Roche Pharma Research and Early Development, Biomics and Pathology, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - Marco Berrera
- Roche Pharma Research and Early Development, Biomics and Pathology, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - Matthias E Lauer
- Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - Philippe Ringler
- Center for Cellular Imaging and NanoAnalytics (C-CINA), University of Basel, Basel, Switzerland
| | - Bettina Nordbo
- Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Copenhagen, F. Hoffmann-La Roche Ltd, Fremtidsvej3, 2970 Hoersholm, Denmark
| | - Marianne Lerbech Jensen
- Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Copenhagen, F. Hoffmann-La Roche Ltd, Fremtidsvej3, 2970 Hoersholm, Denmark
| | - Filippo Sladojevich
- Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - Ravi Jagasia
- Roche Pharma Research and Early Development, Neurology and Rare Diseases Disease Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - Rainer Alex
- Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - Remo Gamboni
- Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - Michael Keller
- Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland.
| |
Collapse
|
16
|
Adapted nano-carriers for gastrointestinal defense components: surface strategies and challenges. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE 2020; 29:102277. [DOI: 10.1016/j.nano.2020.102277] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/12/2020] [Revised: 06/18/2020] [Accepted: 07/18/2020] [Indexed: 12/21/2022]
|
17
|
Karabasz A, Szuwarzyński M, Nowakowska M, Bzowska M, Lewandowska-Łańcucka J. Stabilization of liposomes with silicone layer improves their elastomechanical properties while not compromising biological features. Colloids Surf B Biointerfaces 2020; 195:111272. [PMID: 32791473 DOI: 10.1016/j.colsurfb.2020.111272] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2020] [Revised: 07/20/2020] [Accepted: 07/21/2020] [Indexed: 11/28/2022]
Abstract
The liposomes are among the most promising types of drug delivery systems but low stability significantly limits their application. Some approaches proposed to overcome this drawback may affect the liposomes toxicity profile. It is assumed that developed by us and presented here stabilization method involving formation of silicone network within the liposomal bilayer will improve elastomechanical properties of vesicles while not deteriorating their biocompatibility. The silicone-stabilized liposomes were prepared by base-catalyzed polycondensation process of the 1,3,5,7-tetramethylcyclotetrasiloxane (D4H) within the liposomal bilayer. The systematic biological in vitro studies of vesicles obtained were carried out. Moreover, the elastomechanical features investigation employing atomic force microscopy (AFM) measurements was performed. These properties of the liposome membrane are of great importance since they define the nanocarriers' stability as well as play a significant role in their cellular uptake via endocytosis. Applying the Derjaguin-Muller-Toporov (DMT) model, the elastic modulus of the silicone-stabilized liposomes was determined and compared to that characteristic for the pristine liposomes. The in vitro biological evaluation of silicone-stabilized liposomes demonstrated that these vesicles are not toxic for blood cells isolated from healthy donors and they do not induce oxidative stress in HepG2 cells. AFM results confirmed the stabilizing effect of silicone and revealed that the silicone network improves the elastomechanical properties of the resulted liposomes. This is the first report demonstrating that the silicone-stabilized liposomes retain biocompatibility of pristine liposomes' while acquire significantly better elastomechanical features.
Collapse
Affiliation(s)
- Alicja Karabasz
- Department of Cell Biochemistry, Faculty of Biochemistry, Biophysics and Biotechnology Jagiellonian University, Gronostajowa 7, 30-387 Kraków, Poland
| | - Michał Szuwarzyński
- AGH University of Science and Technology, Academic Centre for Materials and Nanotechnology, Al. Mickiewicza 30, 30-059 Krakow, Poland
| | - Maria Nowakowska
- Department of Physical Chemistry, Faculty of Chemistry, Jagiellonian University, Gronostajowa 2, 30-387 Kraków, Poland
| | - Monika Bzowska
- Department of Cell Biochemistry, Faculty of Biochemistry, Biophysics and Biotechnology Jagiellonian University, Gronostajowa 7, 30-387 Kraków, Poland.
| | - Joanna Lewandowska-Łańcucka
- Department of Physical Chemistry, Faculty of Chemistry, Jagiellonian University, Gronostajowa 2, 30-387 Kraków, Poland.
| |
Collapse
|
18
|
Manconi M, Caddeo C, Manca ML, Fadda AM. Oral delivery of natural compounds by phospholipid vesicles. Nanomedicine (Lond) 2020; 15:1795-1803. [PMID: 32698672 DOI: 10.2217/nnm-2020-0085] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
The purpose of this report is to summarize and critically analyze emerging trends in phospholipid vesicles for the oral delivery of natural compounds. Liposomes have long been used as delivery systems, thanks to their ability to incorporate diverse bioactives, their biocompatibility and safety. However, the efficacy of oral liposomes is hampered by their low stability under the harsh conditions of the gastrointestinal tract. Different approaches have been utilized with the aim of improving the stability of liposomes and the payload after oral administration. This report provides an overview on the phospholipid vesicles used for oral delivery of natural compounds, exploring the current strategies to improve their performance by modifying the lipid bilayer composition and assembly or the physical state.
Collapse
Affiliation(s)
- Maria Manconi
- Department of Life & Environmental Sciences, University of Cagliari, Via Ospedale 72, Cagliari, 09124, Italy
| | - Carla Caddeo
- Department of Life & Environmental Sciences, University of Cagliari, Via Ospedale 72, Cagliari, 09124, Italy
| | - Maria Letizia Manca
- Department of Life & Environmental Sciences, University of Cagliari, Via Ospedale 72, Cagliari, 09124, Italy
| | - Anna Maria Fadda
- Department of Life & Environmental Sciences, University of Cagliari, Via Ospedale 72, Cagliari, 09124, Italy
| |
Collapse
|
19
|
Minami K, Takazawa A, Taniguchi Y, Higashino H, Kataoka M, Asai T, Oku N, Yamashita S. Challenge for oral delivery of middle-molecular drugs: Use of osmolarity-sensitive liposome as a drug carrier in the GI tract. J Drug Deliv Sci Technol 2020. [DOI: 10.1016/j.jddst.2019.04.035] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
20
|
An in vitro digestion study of encapsulated lactoferrin in rapeseed phospholipid-based liposomes. Food Chem 2020; 321:126717. [PMID: 32259734 DOI: 10.1016/j.foodchem.2020.126717] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2019] [Revised: 03/28/2020] [Accepted: 03/30/2020] [Indexed: 12/23/2022]
Abstract
Effectiveness of liposomes elaborated with rapeseed phospholipid (RP) extracted from a residue of oil processing, stigmasterol (ST) and/or hydrogenated phosphatidylcholine (HPC) for the encapsulation lactoferrin (LF) was studied; lipid membrane of liposomes was characterized (bilayer size, chain conformational order, lateral packing, lipid phase, and morphology) and the protection offered to the encapsulated LF during in vitro digestion was determined. Liposomes composed of RP+STLC(low concentration) showed spherical and irregular vesicles without perforations. Lamellar structure was organized in a liquid-ordered phase with a potential orthorhombic packing. Stability and size of the liposomes were more affected by gastric digestion than intestinal digestion; 67-80% of the initially encapsulated LF remained intact after gastric digestion whereas the percentage was reduced to 16-35% after intestinal digestion. Our results shows that liposomes elaborated with RP, properly combined with other lipids, can be a useful oral delivery system of molecules sensitive to digestive enzymes.
Collapse
|
21
|
Liposomes for Enhanced Bioavailability of Water-Insoluble Drugs: In Vivo Evidence and Recent Approaches. Pharmaceutics 2020; 12:pharmaceutics12030264. [PMID: 32183185 PMCID: PMC7151102 DOI: 10.3390/pharmaceutics12030264] [Citation(s) in RCA: 116] [Impact Index Per Article: 29.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2020] [Revised: 03/07/2020] [Accepted: 03/10/2020] [Indexed: 12/26/2022] Open
Abstract
It has been known that a considerable number of drugs in clinical use or under development are water-insoluble drugs with poor bioavailability (BA). The liposomal delivery system has drawn attention as one of the noteworthy approaches to increase dissolution and subsequently absorption in the gastrointestinal (GI) tract because of its biocompatibility and ability to encapsulate hydrophobic molecules in the lipid domain. However, there have been several drawbacks, such as structural instability in the GI tract and poor permeability across intestinal epithelia because of its relatively large size. In addition, there have been no liposomal formulations approved for oral use to date, despite the success of parenteral liposomes. Nevertheless, liposomal oral delivery has resurged with the rapid increase of published studies in the last decade. However, it is discouraging that most of this research has been in vitro studies only and there have not been many water-insoluble drugs with in vivo data. The present review focused on the in vivo evidence for the improved BA of water-insoluble drugs using liposomes to resolve doubts raised concerning liposomal oral delivery and attempted to provide insight by highlighting the approaches used for in vivo achievements.
Collapse
|
22
|
Matoori S, Bao Y, Schmidt A, Fischer EJ, Ochoa-Sanchez R, Tremblay M, Oliveira MM, Rose CF, Leroux JC. An Investigation of PS-b-PEO Polymersomes for the Oral Treatment and Diagnosis of Hyperammonemia. SMALL (WEINHEIM AN DER BERGSTRASSE, GERMANY) 2019; 15:e1902347. [PMID: 31721441 DOI: 10.1002/smll.201902347] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/09/2019] [Revised: 10/02/2019] [Indexed: 05/17/2023]
Abstract
Ammonia-scavenging transmembrane pH-gradient poly(styrene)-b-poly(ethylene oxide) polymersomes are investigated for the oral treatment and diagnosis of hyperammonemia, a condition associated with serious neurologic complications in patients with liver disease as well as in infants with urea cycle disorders. While these polymersomes are highly stable in simulated intestinal fluids at extreme bile salt and osmolality conditions, they unexpectedly do not reduce plasmatic ammonia levels in cirrhotic rats after oral dosing. Incubation in dietary fiber hydrogels mimicking the colonic environment suggests that the vesicles are probably destabilized during the dehydration of the intestinal chyme. The findings question the relevance of commonly used simulated intestinal fluids for studying vesicular stability. With the encapsulation of a pH-sensitive dye in the polymersome core, the local pH increase upon ammonia influx could be exploited to assess the ammonia concentration in the plasma of healthy and cirrhotic rats as well as in other fluids. Due to its high sensitivity and selectivity, this polymersome-based assay could prove useful in the monitoring of hyperammonemic patients and in other applications such as drug screening tests.
Collapse
Affiliation(s)
- Simon Matoori
- Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, 8093, Switzerland
| | - Yinyin Bao
- Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, 8093, Switzerland
| | - Aaron Schmidt
- Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, 8093, Switzerland
| | - Eric J Fischer
- Institute for Chemical and Bioengineering, Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, 8093, Switzerland
| | | | - Mélanie Tremblay
- Hepato-Neuro Laboratory, CRCHUM, Montréal, H2X 0A9, Québec, Canada
| | | | | | - Jean-Christophe Leroux
- Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, 8093, Switzerland
| |
Collapse
|
23
|
Abstract
Abstract
Primaquine (PQ) has long been recognized as the only effective drug in the treatment of hepatic stage malaria. However, severe toxicity limits its therapeutical application. Combining PQ with chloroquine (CQ) has been reported as enhancing the former’s efficacy, while simultaneously reducing its toxicity. In this study, the optimal conditions for encapsulating PQ-CQ in liposome, including incubation time, temperature and drug to lipid ratio, were identified. Furthermore, the effect of the loading combination of these two drugs on liposomal characteristics and the drug released from liposome was evaluated. Liposome is composed of HSPC, cholesterol and DSPE-mPEG2000 at a molar ratio of 55:40:5 and the drugs were loaded by means of the transmembrane pH gradient method. The particle size, ζ-potential and drug encapsulation efficiency were subsequently evaluated. The results showed that all liposome was produced with a similar particle size and ζ -potential. PQ and CQ could be optimally loaded into liposome by incubating the mixtures at 60°C for 20 minutes at a respective drug to lipid ratio of 1:3 for PQ and CQ. However, compared to single drug loading, dual-loading of PQ+CQ into liposome resulted in lower drug encapsulation and slower drug release. In conclusion, PQ and CQ can be jointly loaded into liposome with differing profiles of encapsulation and drug release.
Collapse
|
24
|
Menina S, Eisenbeis J, Kamal MAM, Koch M, Bischoff M, Gordon S, Loretz B, Lehr C. Bioinspired Liposomes for Oral Delivery of Colistin to Combat Intracellular Infections by Salmonella enterica. Adv Healthc Mater 2019; 8:e1900564. [PMID: 31328434 DOI: 10.1002/adhm.201900564] [Citation(s) in RCA: 38] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2019] [Revised: 06/27/2019] [Indexed: 01/07/2023]
Abstract
Bacterial invasion into eukaryotic cells and the establishment of intracellular infection has proven to be an effective means of resisting antibiotic action, as anti-infective agents commonly exhibit a poor permeability across the host cell membrane. Encapsulation of anti-infectives into nanoscaled delivery systems, such as liposomes, is shown to result in an enhancement of intracellular delivery. The aim of the current work is, therefore, to formulate colistin, a poorly permeable anti-infective, into liposomes suitable for oral delivery, and to functionalize these carriers with a bacteria-derived invasive moiety to enhance their intracellular delivery. Different combinations of phospholipids and cholesterol are explored to optimize liposomal drug encapsulation and stability in biorelevant media. These liposomes are then surface-functionalized with extracellular adherence protein (Eap), derived from Staphylococcus aureus. Treatment of HEp-2 and Caco-2 cells infected with Salmonella enterica using colistin-containing, Eap-functionalized liposomes resulted in a significant reduction of intracellular bacteria, in comparison to treatment with nonfunctionalized liposomes as well as colistin alone. This indicates that such bio-invasive carriers are able to facilitate intracellular delivery of colistin, as necessary for intracellular anti-infective activity. The developed Eap-functionalized liposomes, therefore, present a promising strategy for improving the therapy of intracellular infections.
Collapse
Affiliation(s)
- Sara Menina
- Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)Helmholtz Center for Infection Research (HZI) Saarbrücken 66123 Germany
- Department of PharmacySaarland University Saarbrücken 66123 Germany
| | - Janina Eisenbeis
- Institute of Medical Microbiology and HygieneSaarland University Homburg 66421 Germany
| | - Mohamed Ashraf M. Kamal
- Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)Helmholtz Center for Infection Research (HZI) Saarbrücken 66123 Germany
| | - Marcus Koch
- Institute for New MaterialsSaarland University Saarbrücken 66123 Germany
| | - Markus Bischoff
- Institute of Medical Microbiology and HygieneSaarland University Homburg 66421 Germany
| | - Sarah Gordon
- Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)Helmholtz Center for Infection Research (HZI) Saarbrücken 66123 Germany
- School of Pharmacy and Biomolecular SciencesJohn Moores University Liverpool L3 3AF UK
| | - Brigitta Loretz
- Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)Helmholtz Center for Infection Research (HZI) Saarbrücken 66123 Germany
| | - Claus‐Michael Lehr
- Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)Helmholtz Center for Infection Research (HZI) Saarbrücken 66123 Germany
- Department of PharmacySaarland University Saarbrücken 66123 Germany
| |
Collapse
|
25
|
Jovanović AA, Balanč BD, Djordjević VB, Ota A, Skrt M, Šavikin KP, Bugarski BM, Nedović VA, Ulrih NP. Effect of gentisic acid on the structural-functional properties of liposomes incorporating β-sitosterol. Colloids Surf B Biointerfaces 2019; 183:110422. [PMID: 31437609 DOI: 10.1016/j.colsurfb.2019.110422] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2019] [Revised: 07/08/2019] [Accepted: 08/02/2019] [Indexed: 01/15/2023]
Abstract
Multifunctional liposomes incorporating β-sitosterol were developed for delivery of gentisic acid (GA). The interactions of both compounds with phospholipid bilayer were interpreted viaeffects of different β-sitosterol content (0, 20 and 50 mol %) and different gentisic acid to lipid ratio (nGA/nlip from 10-5 to 1) on membrane fluidity and thermotropic properties. Multilamellar vesicles of phosphatidylcholines (with size range between 1350 and 1900 nm) effectively encapsulated GA (54%) when nGA/nlip was higher than 0.01. Suppression of lipid peroxidation was directly related to concentration of GA. The resistance to diffusion of gentisic acid from liposomes increased for ˜50% in samples incorporating 50 mol % β-sitosterol compared to sterol-free liposomes. Finally, simulated in vitro gastrointestinal conditions showed that the release was mainly affected by low pH of simulated gastric fluid and the presence of cholates in simulated intestinal fluid, rather than by enzymes activity.
Collapse
Affiliation(s)
- Aleksandra A Jovanović
- Department of Chemical Engineering, Faculty of Technology and Metallurgy, University of Belgrade, Karnegijeva 4, 11000 Belgrade, Serbia
| | - Bojana D Balanč
- Department of Chemical Engineering, Faculty of Technology and Metallurgy, University of Belgrade, Karnegijeva 4, 11000 Belgrade, Serbia
| | - Verica B Djordjević
- Department of Chemical Engineering, Faculty of Technology and Metallurgy, University of Belgrade, Karnegijeva 4, 11000 Belgrade, Serbia
| | - Ajda Ota
- Department of Food Science and Technology, Biotechnical Faculty, University of Ljubljana, Jamnikarjeva 101, 1000 Ljubljana, Slovenia
| | - Mihaela Skrt
- Department of Food Science and Technology, Biotechnical Faculty, University of Ljubljana, Jamnikarjeva 101, 1000 Ljubljana, Slovenia
| | - Katarina P Šavikin
- Institute for Medicinal Plant Research "Dr Josif Pančić", Tadeuša Košćuška 1, 11000 Belgrade, Serbia
| | - Branko M Bugarski
- Department of Chemical Engineering, Faculty of Technology and Metallurgy, University of Belgrade, Karnegijeva 4, 11000 Belgrade, Serbia
| | - Viktor A Nedović
- Department of Food Technology and Biochemistry, Faculty of Agriculture, University of Belgrade, Nemanjina 6, 11080 Belgrade, Serbia
| | - Nataša Poklar Ulrih
- Department of Food Science and Technology, Biotechnical Faculty, University of Ljubljana, Jamnikarjeva 101, 1000 Ljubljana, Slovenia.
| |
Collapse
|
26
|
Marazioti A, Papadia K, Kannavou M, Spella M, Basta A, de Lastic AL, Rodi M, Mouzaki A, Samiotaki M, Panayotou G, Stathopoulos GT, Antimisiaris SG. Cellular Vesicles: New Insights in Engineering Methods, Interaction with Cells and Potential for Brain Targeting. J Pharmacol Exp Ther 2019; 370:772-785. [PMID: 31061141 DOI: 10.1124/jpet.119.257097] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2019] [Accepted: 04/30/2019] [Indexed: 12/31/2022] Open
Abstract
Cellular vesicles (CVs) have been proposed as alternatives to exosomes for targeted drug delivery. CVs, prepared from human embryonic kidney 293 cells (HEK-293), C57BL/6 mouse B16F10 skin melanoma cells (B16F10), and immortalized human cerebral microvascular endothelial cells (hCMEC/D3) by liposome technology methods, were characterized for morphology, cytotoxicity, and cell uptake properties. CV brain-targeting potential was evaluated in vitro on the hCMEC/D3 blood-brain barrier (BBB) model, and in vivo/ex vivo. CV sizes were between 135 and 285 nm, and the ζ-potential was negative. The dehydration-rehydration method conferred highest calcein loading and latency to CVs compared with other methods. The increased calcein leakage from CVs when compared with liposomes indicated their poor integrity, which was increased by pegylation. The in vivo results confirmed lower liver uptake by PEG-CVs (compared with nonpegylated) proving that the calcein integrity test is useful for prediction of CV biodistribution, as used for liposomes. The cell uptake of homologous origin CVs was not always higher compared with that of non-homologous. Nevertheless, CVs from hCMEC/D3 demonstrated the highest BBB permeability (in vitro) compared with OX-26 targeted liposomes, and brain localization (in vivo). CVs from hCMEC/D3 cells grown in different media demonstrated decreased interaction with brain cells and brain localization. Significant differences in proteome of the two latter CV types were identified by proteomics, suggesting a potential methodology for identification of organotropism-determining CV components.
Collapse
Affiliation(s)
- A Marazioti
- Foundation for Research and Technology Hellas, Institute of Chemical Engineering Sciences, FORTH/ICE-HT, Rio, Greece (A.M., M.K., A.B., S.G.A.); Laboratory of Pharmaceutical Technology, Department of Pharmacy (K.P., M.K., A.B., S.G.A.) and Laboratory for Molecular Respiratory Carcinogenesis, Department of Physiology, Faculty of Medicine (M.Sp., G.T.S.), University of Patras, Rio, Greece; Laboratory of Immunohematology, Division of Hematology, Department of Internal Medicine, Medical School, University of Patras, Patras, Greece (A.-L.d.L., M.R., A.M.); B.S.R.C. Alexander Fleming, Vari, Attica, Greece (M.Sa., G.P.); and Comprehensive Pneumology Center and Institute for Lung Biology and Disease, University Hospital, Ludwig-Maximilians University and Helmholtz Center Munich, Member of the German Center for Lung Research, Munich, Bavaria, Germany (G.T.S.)
| | - K Papadia
- Foundation for Research and Technology Hellas, Institute of Chemical Engineering Sciences, FORTH/ICE-HT, Rio, Greece (A.M., M.K., A.B., S.G.A.); Laboratory of Pharmaceutical Technology, Department of Pharmacy (K.P., M.K., A.B., S.G.A.) and Laboratory for Molecular Respiratory Carcinogenesis, Department of Physiology, Faculty of Medicine (M.Sp., G.T.S.), University of Patras, Rio, Greece; Laboratory of Immunohematology, Division of Hematology, Department of Internal Medicine, Medical School, University of Patras, Patras, Greece (A.-L.d.L., M.R., A.M.); B.S.R.C. Alexander Fleming, Vari, Attica, Greece (M.Sa., G.P.); and Comprehensive Pneumology Center and Institute for Lung Biology and Disease, University Hospital, Ludwig-Maximilians University and Helmholtz Center Munich, Member of the German Center for Lung Research, Munich, Bavaria, Germany (G.T.S.)
| | - M Kannavou
- Foundation for Research and Technology Hellas, Institute of Chemical Engineering Sciences, FORTH/ICE-HT, Rio, Greece (A.M., M.K., A.B., S.G.A.); Laboratory of Pharmaceutical Technology, Department of Pharmacy (K.P., M.K., A.B., S.G.A.) and Laboratory for Molecular Respiratory Carcinogenesis, Department of Physiology, Faculty of Medicine (M.Sp., G.T.S.), University of Patras, Rio, Greece; Laboratory of Immunohematology, Division of Hematology, Department of Internal Medicine, Medical School, University of Patras, Patras, Greece (A.-L.d.L., M.R., A.M.); B.S.R.C. Alexander Fleming, Vari, Attica, Greece (M.Sa., G.P.); and Comprehensive Pneumology Center and Institute for Lung Biology and Disease, University Hospital, Ludwig-Maximilians University and Helmholtz Center Munich, Member of the German Center for Lung Research, Munich, Bavaria, Germany (G.T.S.)
| | - M Spella
- Foundation for Research and Technology Hellas, Institute of Chemical Engineering Sciences, FORTH/ICE-HT, Rio, Greece (A.M., M.K., A.B., S.G.A.); Laboratory of Pharmaceutical Technology, Department of Pharmacy (K.P., M.K., A.B., S.G.A.) and Laboratory for Molecular Respiratory Carcinogenesis, Department of Physiology, Faculty of Medicine (M.Sp., G.T.S.), University of Patras, Rio, Greece; Laboratory of Immunohematology, Division of Hematology, Department of Internal Medicine, Medical School, University of Patras, Patras, Greece (A.-L.d.L., M.R., A.M.); B.S.R.C. Alexander Fleming, Vari, Attica, Greece (M.Sa., G.P.); and Comprehensive Pneumology Center and Institute for Lung Biology and Disease, University Hospital, Ludwig-Maximilians University and Helmholtz Center Munich, Member of the German Center for Lung Research, Munich, Bavaria, Germany (G.T.S.)
| | - A Basta
- Foundation for Research and Technology Hellas, Institute of Chemical Engineering Sciences, FORTH/ICE-HT, Rio, Greece (A.M., M.K., A.B., S.G.A.); Laboratory of Pharmaceutical Technology, Department of Pharmacy (K.P., M.K., A.B., S.G.A.) and Laboratory for Molecular Respiratory Carcinogenesis, Department of Physiology, Faculty of Medicine (M.Sp., G.T.S.), University of Patras, Rio, Greece; Laboratory of Immunohematology, Division of Hematology, Department of Internal Medicine, Medical School, University of Patras, Patras, Greece (A.-L.d.L., M.R., A.M.); B.S.R.C. Alexander Fleming, Vari, Attica, Greece (M.Sa., G.P.); and Comprehensive Pneumology Center and Institute for Lung Biology and Disease, University Hospital, Ludwig-Maximilians University and Helmholtz Center Munich, Member of the German Center for Lung Research, Munich, Bavaria, Germany (G.T.S.)
| | - A-L de Lastic
- Foundation for Research and Technology Hellas, Institute of Chemical Engineering Sciences, FORTH/ICE-HT, Rio, Greece (A.M., M.K., A.B., S.G.A.); Laboratory of Pharmaceutical Technology, Department of Pharmacy (K.P., M.K., A.B., S.G.A.) and Laboratory for Molecular Respiratory Carcinogenesis, Department of Physiology, Faculty of Medicine (M.Sp., G.T.S.), University of Patras, Rio, Greece; Laboratory of Immunohematology, Division of Hematology, Department of Internal Medicine, Medical School, University of Patras, Patras, Greece (A.-L.d.L., M.R., A.M.); B.S.R.C. Alexander Fleming, Vari, Attica, Greece (M.Sa., G.P.); and Comprehensive Pneumology Center and Institute for Lung Biology and Disease, University Hospital, Ludwig-Maximilians University and Helmholtz Center Munich, Member of the German Center for Lung Research, Munich, Bavaria, Germany (G.T.S.)
| | - M Rodi
- Foundation for Research and Technology Hellas, Institute of Chemical Engineering Sciences, FORTH/ICE-HT, Rio, Greece (A.M., M.K., A.B., S.G.A.); Laboratory of Pharmaceutical Technology, Department of Pharmacy (K.P., M.K., A.B., S.G.A.) and Laboratory for Molecular Respiratory Carcinogenesis, Department of Physiology, Faculty of Medicine (M.Sp., G.T.S.), University of Patras, Rio, Greece; Laboratory of Immunohematology, Division of Hematology, Department of Internal Medicine, Medical School, University of Patras, Patras, Greece (A.-L.d.L., M.R., A.M.); B.S.R.C. Alexander Fleming, Vari, Attica, Greece (M.Sa., G.P.); and Comprehensive Pneumology Center and Institute for Lung Biology and Disease, University Hospital, Ludwig-Maximilians University and Helmholtz Center Munich, Member of the German Center for Lung Research, Munich, Bavaria, Germany (G.T.S.)
| | - A Mouzaki
- Foundation for Research and Technology Hellas, Institute of Chemical Engineering Sciences, FORTH/ICE-HT, Rio, Greece (A.M., M.K., A.B., S.G.A.); Laboratory of Pharmaceutical Technology, Department of Pharmacy (K.P., M.K., A.B., S.G.A.) and Laboratory for Molecular Respiratory Carcinogenesis, Department of Physiology, Faculty of Medicine (M.Sp., G.T.S.), University of Patras, Rio, Greece; Laboratory of Immunohematology, Division of Hematology, Department of Internal Medicine, Medical School, University of Patras, Patras, Greece (A.-L.d.L., M.R., A.M.); B.S.R.C. Alexander Fleming, Vari, Attica, Greece (M.Sa., G.P.); and Comprehensive Pneumology Center and Institute for Lung Biology and Disease, University Hospital, Ludwig-Maximilians University and Helmholtz Center Munich, Member of the German Center for Lung Research, Munich, Bavaria, Germany (G.T.S.)
| | - M Samiotaki
- Foundation for Research and Technology Hellas, Institute of Chemical Engineering Sciences, FORTH/ICE-HT, Rio, Greece (A.M., M.K., A.B., S.G.A.); Laboratory of Pharmaceutical Technology, Department of Pharmacy (K.P., M.K., A.B., S.G.A.) and Laboratory for Molecular Respiratory Carcinogenesis, Department of Physiology, Faculty of Medicine (M.Sp., G.T.S.), University of Patras, Rio, Greece; Laboratory of Immunohematology, Division of Hematology, Department of Internal Medicine, Medical School, University of Patras, Patras, Greece (A.-L.d.L., M.R., A.M.); B.S.R.C. Alexander Fleming, Vari, Attica, Greece (M.Sa., G.P.); and Comprehensive Pneumology Center and Institute for Lung Biology and Disease, University Hospital, Ludwig-Maximilians University and Helmholtz Center Munich, Member of the German Center for Lung Research, Munich, Bavaria, Germany (G.T.S.)
| | - G Panayotou
- Foundation for Research and Technology Hellas, Institute of Chemical Engineering Sciences, FORTH/ICE-HT, Rio, Greece (A.M., M.K., A.B., S.G.A.); Laboratory of Pharmaceutical Technology, Department of Pharmacy (K.P., M.K., A.B., S.G.A.) and Laboratory for Molecular Respiratory Carcinogenesis, Department of Physiology, Faculty of Medicine (M.Sp., G.T.S.), University of Patras, Rio, Greece; Laboratory of Immunohematology, Division of Hematology, Department of Internal Medicine, Medical School, University of Patras, Patras, Greece (A.-L.d.L., M.R., A.M.); B.S.R.C. Alexander Fleming, Vari, Attica, Greece (M.Sa., G.P.); and Comprehensive Pneumology Center and Institute for Lung Biology and Disease, University Hospital, Ludwig-Maximilians University and Helmholtz Center Munich, Member of the German Center for Lung Research, Munich, Bavaria, Germany (G.T.S.)
| | - G T Stathopoulos
- Foundation for Research and Technology Hellas, Institute of Chemical Engineering Sciences, FORTH/ICE-HT, Rio, Greece (A.M., M.K., A.B., S.G.A.); Laboratory of Pharmaceutical Technology, Department of Pharmacy (K.P., M.K., A.B., S.G.A.) and Laboratory for Molecular Respiratory Carcinogenesis, Department of Physiology, Faculty of Medicine (M.Sp., G.T.S.), University of Patras, Rio, Greece; Laboratory of Immunohematology, Division of Hematology, Department of Internal Medicine, Medical School, University of Patras, Patras, Greece (A.-L.d.L., M.R., A.M.); B.S.R.C. Alexander Fleming, Vari, Attica, Greece (M.Sa., G.P.); and Comprehensive Pneumology Center and Institute for Lung Biology and Disease, University Hospital, Ludwig-Maximilians University and Helmholtz Center Munich, Member of the German Center for Lung Research, Munich, Bavaria, Germany (G.T.S.)
| | - S G Antimisiaris
- Foundation for Research and Technology Hellas, Institute of Chemical Engineering Sciences, FORTH/ICE-HT, Rio, Greece (A.M., M.K., A.B., S.G.A.); Laboratory of Pharmaceutical Technology, Department of Pharmacy (K.P., M.K., A.B., S.G.A.) and Laboratory for Molecular Respiratory Carcinogenesis, Department of Physiology, Faculty of Medicine (M.Sp., G.T.S.), University of Patras, Rio, Greece; Laboratory of Immunohematology, Division of Hematology, Department of Internal Medicine, Medical School, University of Patras, Patras, Greece (A.-L.d.L., M.R., A.M.); B.S.R.C. Alexander Fleming, Vari, Attica, Greece (M.Sa., G.P.); and Comprehensive Pneumology Center and Institute for Lung Biology and Disease, University Hospital, Ludwig-Maximilians University and Helmholtz Center Munich, Member of the German Center for Lung Research, Munich, Bavaria, Germany (G.T.S.)
| |
Collapse
|
27
|
Anionic versus cationic bilosomes as oral nanocarriers for enhanced delivery of the hydrophilic drug risedronate. Int J Pharm 2019; 564:410-425. [PMID: 31029657 DOI: 10.1016/j.ijpharm.2019.04.069] [Citation(s) in RCA: 35] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2019] [Revised: 04/16/2019] [Accepted: 04/24/2019] [Indexed: 01/20/2023]
Abstract
Albeit its well known potency as a postmenopausal osteoporosis treatment, Risedronate suffers from poor oral bioavailability and high oral toxicity. This is the first work to assess the potential of bilosomes to address challenges of RS oral delivery. Furthermore, impact of integrating cationic moiety into bilosomes on intestinal digestability and toxicity of RS nanovesicles was first investigated in this article. Prepared formulations were optimized based on physicochemical properties, digestibility, intestinal permeation and local toxicity studies. Optimized preparations were prepared by reversed phase evaporation technique with three extrusion cycles and loaded by 10 mg/ml RS. Molar lipid to bile salt to cholesterol ratio was adjusted to 4:1:1 at pH 5. Addition of cholesterol had significantly improved bilosomes stability to digestive media. Results also revealed that permeation of anionic vesicles increased permeation by 1.5 times more than RS solution and reduced drug toxicity by 2 folds. On the other hand, Cationic bilosomes showed good stability in GIT fluids but their induced oral toxicity could limit their use. In conclusion, bilosomes are superior over liposomes regarding protection of delivery system from the damaging effect of external in digestive bile salts. In addition, it decreases toxicity issues of orally administered drugs.
Collapse
|
28
|
He H, Lu Y, Qi J, Zhu Q, Chen Z, Wu W. Adapting liposomes for oral drug delivery. Acta Pharm Sin B 2019; 9:36-48. [PMID: 30766776 PMCID: PMC6362257 DOI: 10.1016/j.apsb.2018.06.005] [Citation(s) in RCA: 320] [Impact Index Per Article: 64.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2018] [Revised: 03/21/2018] [Accepted: 04/12/2018] [Indexed: 02/08/2023] Open
Abstract
Liposomes mimic natural cell membranes and have long been investigated as drug carriers due to excellent entrapment capacity, biocompatibility and safety. Despite the success of parenteral liposomes, oral delivery of liposomes is impeded by various barriers such as instability in the gastrointestinal tract, difficulties in crossing biomembranes, and mass production problems. By modulating the compositions of the lipid bilayers and adding polymers or ligands, both the stability and permeability of liposomes can be greatly improved for oral drug delivery. This review provides an overview of the challenges and current approaches toward the oral delivery of liposomes.
Collapse
Key Words
- APC, antigen-presenting cell
- AUC, area under curve
- Absorption
- BSA, bovine serum albumin
- Bioavailability
- DC, dendritic cells
- DMPC, dimyristoyl phosphatidyl choline
- DPPC, dipalmitoyl phosphotidylcholine
- Drug delivery
- FAE, follicle-associated epithelia
- FITC, fluorescein isothiocyannate
- GIT, gastrointestinal tract
- LUV, large unilamellar vesicles
- Liposomes
- MLV, multilamellar vesicles
- MRT, mean residence time
- MVL, multivesicular liposomes
- Oral
- PC, phosphatidylcholine
- PEG, polyethylene glycol
- RES, reticulo-endothelial
- SC, sodium cholate
- SDC, sodium deoxycholate
- SGC, sodium glycocholate
- SPC, soy phosphatidylcholine
- STC, sodium taurocholate
- SUV, small unilamellar vesicles
- Stability
- TPGS, tocopherol polyethylene glycol succinate
- Tgel, gelling temperature
- Tp, phase transition temperature
- UEA 1, ulex europaeus agglutinin 1
- WGA, wheat germ agglutinin
- rhEGF, recombinant human epithelial growth factor
Collapse
Affiliation(s)
- Haisheng He
- Key Laboratory of Smart Drug Delivery of MOE and PLA, School of Pharmacy, Fudan University, Shanghai 201203, China
| | - Yi Lu
- Key Laboratory of Smart Drug Delivery of MOE and PLA, School of Pharmacy, Fudan University, Shanghai 201203, China
- Shanghai Dermatology Hospital, Shanghai 200443, China
| | - Jianping Qi
- Key Laboratory of Smart Drug Delivery of MOE and PLA, School of Pharmacy, Fudan University, Shanghai 201203, China
- Shanghai Dermatology Hospital, Shanghai 200443, China
| | - Quangang Zhu
- Shanghai Dermatology Hospital, Shanghai 200443, China
| | | | - Wei Wu
- Key Laboratory of Smart Drug Delivery of MOE and PLA, School of Pharmacy, Fudan University, Shanghai 201203, China
- Shanghai Dermatology Hospital, Shanghai 200443, China
| |
Collapse
|
29
|
Wong CY, Al-Salami H, Dass CR. Recent advancements in oral administration of insulin-loaded liposomal drug delivery systems for diabetes mellitus. Int J Pharm 2018; 549:201-217. [DOI: 10.1016/j.ijpharm.2018.07.041] [Citation(s) in RCA: 55] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2018] [Revised: 07/14/2018] [Accepted: 07/18/2018] [Indexed: 11/30/2022]
|
30
|
Churio O, Valenzuela C. Development and characterization of maltodextrin microparticles to encapsulate heme and non-heme iron. Lebensm Wiss Technol 2018. [DOI: 10.1016/j.lwt.2018.05.072] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
|
31
|
Preparation and characterization of iron-alginate beads with some types of iron used in supplementation and fortification strategies. Food Hydrocoll 2018. [DOI: 10.1016/j.foodhyd.2017.07.020] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
|
32
|
Mohsen AM, Asfour MH, Salama AAA. Improved hepatoprotective activity of silymarin via encapsulation in the novel vesicular nanosystem bilosomes. Drug Dev Ind Pharm 2017; 43:2043-2054. [DOI: 10.1080/03639045.2017.1361968] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
33
|
Daeihamed M, Haeri A, Ostad SN, Akhlaghi MF, Dadashzadeh S. Doxorubicin-loaded liposomes: enhancing the oral bioavailability by modulation of physicochemical characteristics. Nanomedicine (Lond) 2017; 12:1187-1202. [DOI: 10.2217/nnm-2017-0007] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Aim: In this study, the effects of liposome characteristics on oral absorption of doxorubicin, as a hydrophilic low-permeability drug, were investigated. Materials & methods: Different doxorubicin-loaded liposomes were prepared, characterized and orally administered to 18 groups of rats. Plasma concentrations of doxorubicin and its aglycone metabolite were measured, and Caco-2 uptake and transport of optimum liposomes were investigated. Results: After studying different factors, a fourfold increase in oral bioavailability was achieved with the non-PEGylated, 120-nm-sized positively charged rigid liposomes (lipid to drug ratio = 10). The extent of drug’s first-pass metabolism as well as endocytosis of nanoparticles were markedly affected by liposomal formulation. Conclusion: Oral absorption is highly dependent on liposomal properties, and optimum formulations are effective for low-permeability drugs.
Collapse
Affiliation(s)
- Marjan Daeihamed
- Department of Pharmaceutics, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Azadeh Haeri
- Department of Pharmaceutics, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Seyed Nasser Ostad
- Department of Toxicology & Pharmacology, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
| | - Masoud Faghih Akhlaghi
- Department of Medicinal Chemistry, School of Pharmacy, Guilan University of Medical Sciences, Rasht, Iran
| | - Simin Dadashzadeh
- Department of Pharmaceutics, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
- Pharmaceutical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| |
Collapse
|
34
|
Wang LH, Shang L, Shan DY, Che X. Long-term floating control-released intravesical preparation of 5-fluorouracil for the local treatment of bladder cancer. Drug Dev Ind Pharm 2017; 43:1343-1350. [PMID: 28402146 DOI: 10.1080/03639045.2017.1318898] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Affiliation(s)
- Li Hong Wang
- School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang, PR China
| | - Lei Shang
- College of Basic Medical Sciences, Shenyang Medical College, Shenyang, PR China
| | - Dong Yuan Shan
- School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang, PR China
| | - Xin Che
- School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, PR China
| |
Collapse
|
35
|
Papadia K, Markoutsa E, Mourtas S, Giannou AD, La Ferla B, Nicotra F, Salmona M, Klepetsanis P, Stathopoulos GT, Antimisiaris SG. Multifunctional LUV liposomes decorated for BBB and amyloid targeting. A. In vitro proof-of-concept. Eur J Pharm Sci 2017; 101:140-148. [PMID: 28193538 DOI: 10.1016/j.ejps.2017.02.019] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2016] [Revised: 01/27/2017] [Accepted: 02/09/2017] [Indexed: 12/24/2022]
Abstract
Multifunctional LUV liposomes (mf-LIPs) were developed, having a curcumin-lipid ligand (TREG) with affinity towards amyloid species, together with ligands to target the transferrin and the LDL receptors of the blood-brain-barrier (BBB), on their surface. mf-LIPs were evaluated for their brain targeting, on hCMEC/D3 monolayers, and for their ability to inhibit Aβ-peptide aggregation. The transport of mf-LIP across hCMEC/D3 monolayers was similar to that of BBB-LIPs, indicating that the presence of TREG on their surface does not reduce their brain targeting potential. Likewise, mf-LIP inhibitory effect on Aβ aggregation was similar to that of LIPs functionalized only with TREG, proving that the presence of brain targeting ligands does not reduce the functionality of the amyloid-specific ligand. Addition of the curcumin-lipid in some liposome types was found to enhance their integrity and reduce the effect of serum proteins on their interaction with brain endothelial cells. Finally, preliminary in vivo results confirm the in vitro findings. Concluding, the current results reveal the potential of the specific curcumin-lipid derivative as a component of multifunctional LIPs with efficient brain targeting capability, intended to act as a theragnostic system for AD.
Collapse
Affiliation(s)
- Konstantina Papadia
- Laboratory of Pharmaceutical Technology, Department of Pharmacy, University of Patras, Rio 26510, Greece
| | - Eleni Markoutsa
- Laboratory of Pharmaceutical Technology, Department of Pharmacy, University of Patras, Rio 26510, Greece
| | - Spyridon Mourtas
- Laboratory of Pharmaceutical Technology, Department of Pharmacy, University of Patras, Rio 26510, Greece
| | - Anastassios D Giannou
- Laboratory for Molecular Respiratory Carcinogenesis, Department of Physiology, Faculty of Medicine, University of Patras, Rio 26504, Greece
| | - Barabara La Ferla
- Department of Biotechnology and Biosciences, University of Milano-Bicocca, Piazza dellaScienza 2, 20126 Milan, Italy
| | - Fransesco Nicotra
- Department of Biotechnology and Biosciences, University of Milano-Bicocca, Piazza dellaScienza 2, 20126 Milan, Italy
| | - Mario Salmona
- Department of Biochemistry and Molecular Pharmacology, Istituto di RicercheFarmacologiche "Mario Negri", Milan, Italy
| | - Pavlos Klepetsanis
- Laboratory of Pharmaceutical Technology, Department of Pharmacy, University of Patras, Rio 26510, Greece; Institute of Chemical Engineering Sciences, FORTH/ICE-HT, Rio 26504, Greece
| | - Georgios T Stathopoulos
- Laboratory for Molecular Respiratory Carcinogenesis, Department of Physiology, Faculty of Medicine, University of Patras, Rio 26504, Greece; Comprehensive Pneumology Center (CPC), Institute for Lung Biology and Disease (iLBD), University Hospital, Ludwig-Maximilians University, Helmholtz Zentrum München (DZL), Munich, Bavaria 81377, Germany
| | - Sophia G Antimisiaris
- Laboratory of Pharmaceutical Technology, Department of Pharmacy, University of Patras, Rio 26510, Greece; Institute of Chemical Engineering Sciences, FORTH/ICE-HT, Rio 26504, Greece.
| |
Collapse
|
36
|
Suchaoin W, Bernkop-Schnürch A. Nanocarriers protecting toward an intestinal pre-uptake metabolism. Nanomedicine (Lond) 2017; 12:255-269. [PMID: 28093952 DOI: 10.2217/nnm-2016-0331] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Pre-uptake metabolism within the GI tract is responsible for the poor oral bioavailability of numerous drugs. As nanocarriers function as a 'shield', protecting incorporated drugs from enzymatic attack, there is an increasing interest in utilizing them as a tool for overcoming drug degradation. Degradation of carriers resulting in the release of incorporated drugs, mucus permeation, enzyme inhibitory properties and their toxicity are crucial factors that must be taken into account when designing proper nanocarriers. The use of polymer- and lipid-based nanocarriers as protective vehicles are discussed within this review. Lipid-based carriers and novel mucopenetrating particles seem to have a great potential in avoiding metabolizing enzymes. Accordingly, nanocarriers are promising tools for improving the bioavailability of drugs, being sensitive to a pre-uptake metabolism.
Collapse
Affiliation(s)
- Wongsakorn Suchaoin
- Department of Pharmaceutical Technology, Institute of Pharmacy, University of Innsbruck, A-6020 Innsbruck, Austria
| | - Andreas Bernkop-Schnürch
- Department of Pharmaceutical Technology, Institute of Pharmacy, University of Innsbruck, A-6020 Innsbruck, Austria
| |
Collapse
|
37
|
Lewandowska-Łańcucka J, Mystek K, Gilarska A, Kamiński K, Romek M, Sulikowski B, Nowakowska M. Silicone-stabilized liposomes as a possible novel nanostructural drug carrier. Colloids Surf B Biointerfaces 2016; 143:359-370. [DOI: 10.1016/j.colsurfb.2016.03.057] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2015] [Revised: 03/17/2016] [Accepted: 03/18/2016] [Indexed: 12/11/2022]
|
38
|
Miatmoko A, Kawano K, Yoda H, Yonemochi E, Hattori Y. Tumor delivery of liposomal doxorubicin prepared with poly-L-glutamic acid as a drug-trapping agent. J Liposome Res 2016; 27:99-107. [PMID: 26982164 DOI: 10.3109/08982104.2016.1166511] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
CONTEXT Poly-l-glutamic acid (PGA) is an anionic polymer with a large number of carboxyl groups that can interact electrostatically with cationic drugs such as doxorubicin (DOX). OBJECTIVE For stable encapsulation of DOX into liposomes, we prepared triethylamine (TEA)-PGA-liposomes using PGA as an internal trapping agent. METHODS We prepared TEA-PGA-liposomes by remote loading of DOX with a TEA gradient into preformed liposomes prepared with 1, 2, or 4 mg/mL PGA (molecular weights 4800, 9800, and 20 500), and evaluated their biodistribution and antitumor effects on Lewis lung carcinoma (LLC) tumor-bearing mice. RESULTS TEA-PGA-liposomes using the higher the molecular weight or concentration of PGA showed a slower release of DOX from the liposomes. TEA-PGA-liposomes prepared with a high concentration of PGA could enhance DOX accumulation in tumors and prolonged DOX circulation in the serum, indicating that DOX may be retained stably in the liposomal interior by interaction with PGA. Furthermore, injection of TEA-PGA-liposomes prepared with 4 mg/mL of PGA9800 or 2 mg/mL PGA20500 strongly inhibited tumor growth in LLC tumor-bearing mice. CONCLUSIONS PGA may be a potential trapping agent for liposomal DOX for tumor drug delivery.
Collapse
Affiliation(s)
| | | | | | - Etsuo Yonemochi
- b Department of Physical Chemistry , Hoshi University , Ebara , Shinagawa , Tokyo , Japan
| | | |
Collapse
|
39
|
Matougui N, Boge L, Groo AC, Umerska A, Ringstad L, Bysell H, Saulnier P. Lipid-based nanoformulations for peptide delivery. Int J Pharm 2016; 502:80-97. [DOI: 10.1016/j.ijpharm.2016.02.019] [Citation(s) in RCA: 72] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2015] [Revised: 01/28/2016] [Accepted: 02/13/2016] [Indexed: 01/24/2023]
|
40
|
Andhariya JV, Burgess DJ. Recent advances in testing of microsphere drug delivery systems. Expert Opin Drug Deliv 2016; 13:593-608. [PMID: 26828874 DOI: 10.1517/17425247.2016.1134484] [Citation(s) in RCA: 35] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
INTRODUCTION This review discusses advances in the field of microsphere testing. AREAS COVERED In vitro release-testing methods such as sample and separate, dialysis membrane sacs and USP apparatus IV have been used for microspheres. Based on comparisons of these methods, USP apparatus IV is currently the method of choice. Accelerated in vitro release tests have been developed to shorten the testing time for quality control purposes. In vitro-in vivo correlations using real-time and accelerated release data have been developed, to minimize the need to conduct in vivo performance evaluation. Storage stability studies have been conducted to investigate the influence of various environmental factors on microsphere quality throughout the product shelf life. New tests such as the floating test and the in vitro wash-off test have been developed along with advancement in characterization techniques for other physico-chemical parameters such as particle size, drug content, and thermal properties. EXPERT OPINION Although significant developments have been made in microsphere release testing, there is still a lack of guidance in this area. Microsphere storage stability studies should be extended to include microspheres containing large molecules. An agreement needs to be reached on the use of particle sizing techniques to avoid inconsistent data. An approach needs to be developed to determine total moisture content of microspheres.
Collapse
Affiliation(s)
- Janki V Andhariya
- a School of Pharmacy , University of Connecticut , Storrs , CT , USA
| | - Diane J Burgess
- a School of Pharmacy , University of Connecticut , Storrs , CT , USA
| |
Collapse
|
41
|
Abstract
The human body has long provided pharmaceutical science with biomaterials of interesting applications. Bile salts (BSs) are biomaterials reminiscent of traditional surfactants with peculiar structure and self-assembled topologies. In the pharmaceutical field, BSs were employed on the basis of two different concepts. The first concept exploited BSs' metabolic and homeostatic functions in disease modulation, whereas the second one utilized BSs' potential to modify drug-delivery characteristics, which recently involved nanotechnology. This review is the first to gather major pharmaceutical applications of BSs from endogenous organotropism up to integration into nanomedicine, with a greater focus on the latter domain. Endogenous applications highlighted the role of BS in modulating hypercholesterolemia and cancer therapy in view of enterohepatic circulation. In addition, recent BS-integrated nanomedicines have been surveyed, chiefly size-tunable cholate nanoparticles, BS-lecithin mixed micelles, bilosomes, probilosomes, and surface-engineered bilosomes. A greater emphasis has been laid on nanosystems for vaccine and cancer therapy. The comparative advantages of BS-integrated nanomedicines over conventional nanocarriers have been noted. Paradoxical effects, current pitfalls, future perspectives, and opinions have also been outlined.
Collapse
Affiliation(s)
- Yosra SR Elnaggar
- Department of Pharmaceutics, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt
| |
Collapse
|
42
|
Liu W, Ye A, Liu W, Liu C, Han J, Singh H. Behaviour of liposomes loaded with bovine serum albumin during in vitro digestion. Food Chem 2015; 175:16-24. [DOI: 10.1016/j.foodchem.2014.11.108] [Citation(s) in RCA: 68] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2014] [Revised: 10/22/2014] [Accepted: 11/18/2014] [Indexed: 12/27/2022]
|
43
|
Mujoo H, Reynolds JNJ, Tucker IG. The influence of bile salts on the response of liposomes to ultrasound. J Liposome Res 2015; 26:87-95. [DOI: 10.3109/08982104.2015.1019515] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
|
44
|
Yao X, Bunt C, Cornish J, Quek SY, Wen J. Oral Delivery of Bovine Lactoferrin Using Pectin- and Chitosan-Modified Liposomes and Solid Lipid Particles: Improvement of Stability of Lactoferrin. Chem Biol Drug Des 2015; 86:466-75. [PMID: 25581616 DOI: 10.1111/cbdd.12509] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2014] [Revised: 12/04/2014] [Accepted: 12/10/2014] [Indexed: 12/30/2022]
Abstract
A critical problem associated with delivery of bovine lactoferrin (bLf) by the oral route is low bioavailability, which is derived from the enzymatic degradation in the gastrointestinal tract and poor permeation across the intestinal epitheliums. Particulate carrier systems have been identified to protect bLf against proteolysis via encapsulation. This study aimed to evaluate the physico-chemical stability of bLf-loaded liposomes and solid lipid particles (SLPs) modified by pectin and chitosan when exposed to various stress conditions. Transmission electron microscopy results showed liposomes and SLPs had a classic shell-core structure with polymer layers surrounded on surface, but the structure appeared to be partially broken after digestion in simulated intestinal fluid (SIF). Although HPLC and sodium dodecyl sulphate-polyacrylamide gel electrophoresis methods qualitatively and quantitatively described either liposomes or SLPs could retain intact bLf against proteolysis in SIF to some extent, all liposome formulations showed rapid rate of lipolysis mediated by pancreatic enzymes. On the other hand, all SLP formulations showed higher heat resistance and greater electrolyte tolerance compared to liposome formulations. After 180 days storage time, liposome-loaded bLf was completely degraded, whereas almost 30% of intact bLf still remained in SLP formulations. Overall, SLPs are considered as primary choice for oral bLf delivery.
Collapse
Affiliation(s)
- Xudong Yao
- School of Pharmacy, Faculty of Medical and Health Science, The University of Auckland, Auckland, 1142, New Zealand
| | - Craig Bunt
- Faculty of Agriculture and Life Science, Lincoln University, Lincoln, 7647, New Zealand
| | - Jillian Cornish
- School of Medicine, Faculty of Medical and Health Science, The University of Auckland, Auckland, 1142, New Zealand
| | - Siew-Young Quek
- School of Chemical Science, The University of Auckland, Auckland, 1142, New Zealand
| | - Jingyuan Wen
- School of Pharmacy, Faculty of Medical and Health Science, The University of Auckland, Auckland, 1142, New Zealand
| |
Collapse
|
45
|
Yaroslavov AA, Zaborova OV, Sybachin AV, Kalashnikova IV, Kesselman E, Schmidt J, Talmon Y, Rodriguez AR, Deming TJ. Biodegradable containers composed of anionic liposomes and cationic polypeptide vesicles. RSC Adv 2015. [DOI: 10.1039/c5ra15863j] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
An electrostatic complexation of liposomes, composed of mixture of anionic and zwitterionic lipids, with bilayer vesicles composed of cationic poly(l-lysine)-b-poly(l-leucine) polypeptides has been investigated.
Collapse
Affiliation(s)
- A. A. Yaroslavov
- Department of Chemistry
- M. V. Lomonosov Moscow State University
- 119991 Moscow
- Russian Federation
| | - O. V. Zaborova
- Department of Chemistry
- M. V. Lomonosov Moscow State University
- 119991 Moscow
- Russian Federation
| | - A. V. Sybachin
- Department of Chemistry
- M. V. Lomonosov Moscow State University
- 119991 Moscow
- Russian Federation
| | - I. V. Kalashnikova
- Department of Chemistry
- M. V. Lomonosov Moscow State University
- 119991 Moscow
- Russian Federation
| | - E. Kesselman
- Department of Chemical Engineering
- Technion-Israel Institute of Technology
- 32000 Haifa
- Israel
| | - J. Schmidt
- Department of Chemical Engineering
- Technion-Israel Institute of Technology
- 32000 Haifa
- Israel
| | - Y. Talmon
- Department of Chemical Engineering
- Technion-Israel Institute of Technology
- 32000 Haifa
- Israel
| | - A. R. Rodriguez
- Department of Bioengineering
- University of California
- Los Angeles
- USA
| | - T. J. Deming
- Department of Bioengineering
- University of California
- Los Angeles
- USA
- Department of Chemistry and Biochemistry
| |
Collapse
|
46
|
Hermida LG, Sabés-Xamaní M, Barnadas-Rodríguez R. Characteristics and behaviour of liposomes when incubated with natural bile salt extract: implications for their use as oral drug delivery systems. SOFT MATTER 2014; 10:6677-6685. [PMID: 25060405 DOI: 10.1039/c4sm00981a] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
The use of liposomes for oral administration of drugs and for food applications is based on their ability to preserve entrapped substances and to increase their bioavailability. Bile salts are one of the agents that affect the liposome structure during intestinal digestion and the main reported studies on liposome/bile salt systems used only one bile salt. The aim of this work is to characterise the interaction of liposomes with a natural bile salt extract (BSE) at physiological pH and temperature. Three types of liposomes (fluid, gel-state and liquid-ordered bilayers) were studied. Phase diagrams were obtained and a very different behaviour was found. Fluid bilayers were completely permeable to an entrapped dye with partial or complete disruption of vesicles (final size 10 nm). Gel-state bilayers released their content but BSE led to the formation of large mixed structures (2000 nm). Liquid-ordered bilayers formed mixed vesicles (1000 nm) and, surprisingly, retained a high percentage of their aqueous content (about 50%). As a consequence, each type of liposome offers singular features to be used in oral applications due to their specific interaction with bile salts.
Collapse
Affiliation(s)
- Laura G Hermida
- Centre of Research and Development in Chemistry, National Institute of Industrial Technology (INTI), Av. Gral. Paz e/ Constituyentes y Albarellos San Martín, Buenos Aires, Argentina
| | | | | |
Collapse
|
47
|
Nguyen TX, Huang L, Liu L, Elamin Abdalla AM, Gauthier M, Yang G. Chitosan-coated nano-liposomes for the oral delivery of berberine hydrochloride. J Mater Chem B 2014; 2:7149-7159. [PMID: 32261793 DOI: 10.1039/c4tb00876f] [Citation(s) in RCA: 87] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Berberine hydrochloride (BH) possesses various pharmacological properties including anticancer; unfortunately, it has low oral bioavailability and potential side effects for its parenteral administration. Nanoscale delivery carriers can increase the oral bioavailability of BH. Chitosan has interesting biopharmaceutical properties such as nontoxicity, biocompatibility, biodegradability, and mucoadhesiveness, and the ability to open epithelial tight junctions. This study aims to engineer a chitosan-coated nano-liposomal carrier for the oral delivery of BH. The engineered formulation had a size in the nanoscale range. Chitosan-coated nano-liposomes displayed better stability and slower BH release in the simulated gastrointestinal (GI) environment as compared to the uncoated ones. All values of pharmacokinetic analysis for chitosan-coated nano-liposomes were higher than for uncoated ones. These findings demonstrate that chitosan-coated nano-liposomes are more efficient than uncoated ones for the oral delivery of BH. It can be concluded that the stability and delayed BH release in the simulated GI environment were improved with engineered chitosan-coated nano-liposomes. Moreover, since desirable in vitro and in vivo characteristics were achieved, they are promising release devices for the oral delivery of BH increasing the bioavailability of the drug.
Collapse
Affiliation(s)
- Thanh Xuan Nguyen
- Department of Biomedical Engineering, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan 430074, China
| | | | | | | | | | | |
Collapse
|
48
|
Wytrwal M, Bednar J, Nowakowska M, Wydro P, Kepczynski M. Interactions of serum with polyelectrolyte-stabilized liposomes: Cryo-TEM studies. Colloids Surf B Biointerfaces 2014; 120:152-9. [DOI: 10.1016/j.colsurfb.2014.02.040] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2013] [Revised: 02/13/2014] [Accepted: 02/22/2014] [Indexed: 11/27/2022]
|
49
|
Luo X, Guan R, Chen X, Tao M, Ma J, Zhao J. Optimization on condition of epigallocatechin-3-gallate (EGCG) nanoliposomes by response surface methodology and cellular uptake studies in Caco-2 cells. NANOSCALE RESEARCH LETTERS 2014; 9:291. [PMID: 24959109 PMCID: PMC4059483 DOI: 10.1186/1556-276x-9-291] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 04/01/2014] [Accepted: 05/30/2014] [Indexed: 06/03/2023]
Abstract
The major component in green tea polyphenols, epigallocatechin-3-gallate (EGCG), has been demonstrated to prevent carcinogenesis. To improve the effectiveness of EGCG, liposomes were used as a carrier in this study. Reverse-phase evaporation method besides response surface methodology is a simple, rapid, and beneficial approach for liposome preparation and optimization. The optimal preparation conditions were as follows: phosphatidylcholine-to-cholesterol ratio of 4.00, EGCG concentration of 4.88 mg/mL, Tween 80 concentration of 1.08 mg/mL, and rotary evaporation temperature of 34.51°C. Under these conditions, the experimental encapsulation efficiency and size of EGCG nanoliposomes were 85.79% ± 1.65% and 180 nm ± 4 nm, which were close with the predicted value. The malondialdehyde value and the release test in vitro indicated that the prepared EGCG nanoliposomes were stable and suitable for more widespread application. Furthermore, compared with free EGCG, encapsulation of EGCG enhanced its inhibitory effect on tumor cell viability at higher concentrations.
Collapse
Affiliation(s)
- Xiaobo Luo
- Zhejiang Provincial Engineering Laboratory of Quality Controlling Technology and Instrumentation for Marine Food, China Jiliang University, XueYuan Road 258#, 310018 Hangzhou, People's Republic of China
| | - Rongfa Guan
- Zhejiang Provincial Engineering Laboratory of Quality Controlling Technology and Instrumentation for Marine Food, China Jiliang University, XueYuan Road 258#, 310018 Hangzhou, People's Republic of China
| | - Xiaoqiang Chen
- Hubei Collaborative Innovation Center for Industrial Fermentation, Hubei University of Technology, Lizhi Road, 430068 Wuhan, China
| | - Miao Tao
- Zhejiang Provincial Key Laboratory of Biometrology and Inspection and Quarantine, China Jiliang University, Hangzhou 310018, People's Republic of China
| | - Jieqing Ma
- Zhejiang Provincial Engineering Laboratory of Quality Controlling Technology and Instrumentation for Marine Food, China Jiliang University, XueYuan Road 258#, 310018 Hangzhou, People's Republic of China
| | - Jin Zhao
- Zhejiang Provincial Engineering Laboratory of Quality Controlling Technology and Instrumentation for Marine Food, China Jiliang University, XueYuan Road 258#, 310018 Hangzhou, People's Republic of China
| |
Collapse
|
50
|
Kraft JC, Freeling JP, Wang Z, Ho RJY. Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems. J Pharm Sci 2014; 103:29-52. [PMID: 24338748 PMCID: PMC4074410 DOI: 10.1002/jps.23773] [Citation(s) in RCA: 332] [Impact Index Per Article: 33.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2013] [Revised: 10/11/2013] [Accepted: 10/14/2013] [Indexed: 12/13/2022]
Abstract
Liposomes are spherical-enclosed membrane vesicles mainly constructed with lipids. Lipid nanoparticles are loaded with therapeutics and may not contain an enclosed bilayer. The majority of those clinically approved have diameters of 50-300 nm. The growing interest in nanomedicine has fueled lipid-drug and lipid-protein studies, which provide a foundation for developing lipid particles that improve drug potency and reduce off-target effects. Integrating advances in lipid membrane research has enabled therapeutic development. At present, about 600 clinical trials involve lipid particle drug delivery systems. Greater understanding of pharmacokinetics, biodistribution, and disposition of lipid-drug particles facilitated particle surface hydration technology (with polyethylene glycol) to reduce rapid clearance and provide sufficient blood circulation time for drug to reach target tissues and cells. Surface hydration enabled the liposome-encapsulated cancer drug doxorubicin (Doxil) to gain clinical approval in 1995. Fifteen lipidic therapeutics are now clinically approved. Although much research involves attaching lipid particles to ligands selective for occult cells and tissues, preparation procedures are often complex and pose scale-up challenges. With emerging knowledge in drug target and lipid-drug distribution in the body, a systems approach that integrates knowledge to design and scale lipid-drug particles may further advance translation of these systems to improve therapeutic safety and efficacy.
Collapse
Affiliation(s)
- John C Kraft
- Department of Pharmaceutics, University of Washington, Seattle, Washington
| | | | | | | |
Collapse
|